KIMBERLY MANHARD - 13 Jul 2022 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
EVP, Drug Development, Director
Signature
/s/ Lisa Peraza Attorney-in-fact for Kimberly Manhard
Issuer symbol
HRTX
Transactions as of
13 Jul 2022
Net transactions value
-$6,056
Form type
4
Filing time
15 Jul 2022, 16:55:01 UTC
Previous filing
26 May 2022
Next filing
27 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Options Exercise +1,250 +11% 12,122 13 Jul 2022 Direct F1
transaction HRTX Common Stock Options Exercise +4,564 +38% 16,686 13 Jul 2022 Direct F1
transaction HRTX Common Stock Tax liability $6,056 -2,012 -12% $3.01 14,674 13 Jul 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -1,250 -10% $0.000000 11,250 13 Jul 2022 Common Stock 1,250 Direct F1, F3
transaction HRTX Restricted Stock Units Options Exercise $0 -4,564 -9.9% $0.000000 41,628 13 Jul 2022 Common Stock 4,564 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F3 The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F4 The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).